2025-05-05 - Analysis Report
## Colgate-Palmolive Co (CL) Stock Review

**0) Introduction:** This report analyzes Colgate-Palmolive Co (CL), a leading consumer goods company specializing in oral hygiene, personal care, and household products.  The analysis incorporates provided financial data, performance metrics, and technical indicators to assess the stock's current status and potential future performance.

**1) Performance Comparison with S&P 500 (VOO):**

Colgate-Palmolive's cumulative return of 37.81% significantly underperformed the S&P 500's 82.57% cumulative return over the analyzed period. The difference is -44.8%, placing it in the 29.4th percentile of its historical range of underperformance relative to the S&P 500 (ranging from -66.7% to 7.8%).

The provided Alpha and Beta analysis reveals mixed performance relative to the market. While Alpha fluctuates, suggesting periods of outperformance and underperformance, the Beta consistently remains above 0.1, indicating higher volatility compared to the market.  The market capitalization (Cap(B)) shows a generally upward trend during the period, however CAGR varied significantly across different 2 years periods.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 16.0% | 4.2% | -16.0% | 0.1 | 51.2 |
| 2016-2018  | -9.0% | 65.3% | -30.0% | 0.1 | 41.4 |
| 2017-2019  | 10.0% | 65.3% | -24.0% | -0.3 | 49.1 |
| 2018-2020  | 22.0% | 65.3% | -8.0% | 0.3 | 62.4 |
| 2019-2021  | 34.0% | 58.5% | -26.0% | 0.8 | 63.7 |
| 2020-2022  | 11.0% | 68.9% | 2.0% | 0.7 | 60.3 |
| 2021-2023  | 8.0% | 68.9% | -13.0% | 0.6 | 62.5 |
| 2022-2024  | 16.0% | 68.9% | -5.0% | 0.5 | 72.9 |
| 2023-2025  | 15.0% | 62.4% | -6.0% | 0.2 | 75.2 |


**2) Recent Price Movement:**

* **Closing Price:** $92.70
* **Last Market Price:** $90.48 (Down $0.23 from previous close)
* **5-Day Moving Average:** $94.52
* **20-Day Moving Average:** $92.81
* **60-Day Moving Average:** $90.45

The price is slightly below the 20-day moving average, suggesting a potential short-term downward trend.  The price is also very close to the 60-day moving average.

**3) Technical Indicators:**

* **Market Risk Indicator (MRI):** 0.4053 (Medium Risk)
* **RSI:** 43.92 (Approaching oversold territory, but not yet there)
* **PPO:** 0.0968 (Positive, indicating potential upward momentum, but weak)
* **20-Day Relative Strength Change:** -9.1% (Short-term weakening)
* **Expected Return:** -88.2% (This extremely negative figure needs further clarification and context.  It's likely an error or requires more detailed explanation.)

The recent price drop of $0.23 does not signify a significant event, such as a sudden surge or decline.

**4) Recent Earnings Analysis:**

| Date       | EPS  | Revenue      |
|------------|------|---------------|
| 2025-04-25 | $0.85 | $4.91 Billion |
| 2024-10-25 | $0.90 | $5.03 Billion |
| 2024-07-26 | $0.89 | $5.06 Billion |
| 2024-04-26 | $0.83 | $5.07 Billion |
| 2025-04-25 | $0.83 | $5.07 Billion | *(Note: Duplicate entry?)*


Revenue remains relatively stable around $5 Billion, with EPS fluctuating slightly.  There is a duplicate entry for 2025-04-25 which needs to be resolved.  Further analysis requires more historical data for a more comprehensive understanding of earnings trends.


**5) Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue  | Profit Margin |
|---------|----------|---------------|
| 2025-03-31 | $4.91B  | 60.82%        |
| 2024-12-31 | $4.95B  | 60.30%        |
| 2024-09-30 | $5.03B  | 61.08%        |
| 2024-06-30 | $5.06B  | 60.62%        |
| 2024-03-31 | $5.07B  | 60.00%        |

Revenue shows a slight downward trend. Profit margins remain consistently high, hovering around 60%.


**Capital and Profitability:**

| Quarter | Equity   | ROE         |
|---------|----------|-------------|
| 2025-03-31 | $0.36B  | 190.08%     |
| 2024-12-31 | $0.21B  | 348.58%     |
| 2024-09-30 | $0.43B  | 169.43%     |
| 2024-06-30 | $0.12B  | 594.31%     |
| 2024-03-31 | $0.23B  | 296.96%     |

Equity and ROE fluctuate significantly.  High ROE figures warrant further investigation into the specific accounting methods used.  Extreme fluctuations suggest potential accounting anomalies that may require further due diligence.

**6) Overall Conclusion:**

Colgate-Palmolive (CL) has underperformed the S&P 500 over the analyzed period. While revenue remains relatively stable and profit margins are high, the recent price movement shows signs of weakening short-term momentum.  The extremely high and fluctuating ROE figures require further scrutiny. The -88.2% expected return is likely an error and needs clarification. Before making any investment decisions, further investigation into the provided data, especially the inconsistencies and extreme values in ROE and the expected return figure, is crucial.  A more thorough analysis incorporating a longer time horizon and more robust financial models is recommended.
